These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19696442)

  • 21. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.
    Ferrer R; Artigas A; Levy MM; Blanco J; González-Díaz G; Garnacho-Montero J; Ibáñez J; Palencia E; Quintana M; de la Torre-Prados MV;
    JAMA; 2008 May; 299(19):2294-303. PubMed ID: 18492971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for severe sepsis and septic shock.
    Sharma VK; Dellinger RP
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):395-403. PubMed ID: 16771617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure to implement evidence-based clinical guidelines for sepsis at the ED.
    De Miguel-Yanes JM; Andueza-Lillo JA; González-Ramallo VJ; Pastor L; Muñoz J
    Am J Emerg Med; 2006 Sep; 24(5):553-9. PubMed ID: 16938593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adherence to international guidelines on early management in severe sepsis and septic shock].
    Quintero RA; Martínez CA; Gamba JD; Ortiz I; Jaimes F
    Biomedica; 2012 Sep; 32(3):449-56. PubMed ID: 23715193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
    Rice TW
    Vasc Health Risk Manag; 2006; 2(1):3-18. PubMed ID: 17319465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current management of sepsis in critically ill adult patients.
    Vincent JL; Serrano EC; Dimoula A
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):847-56. PubMed ID: 21810056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign.
    Casserly B; Gerlach H; Phillips GS; Marshall JC; Lemeshow S; Levy MM
    Crit Care Med; 2012 May; 40(5):1417-26. PubMed ID: 22430247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
    Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
    Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of sepsis in the surgical intensive care unit.
    Carney DE; Matsushima K; Frankel HL
    Isr Med Assoc J; 2011 Nov; 13(11):694-9. PubMed ID: 22279706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The new aspects of treatment of severe sepsis and septic shock].
    Adukauskiene D; Rimdeika R; Vitkauskiene A; Pilvinis V; Cicinskaite I
    Medicina (Kaunas); 2006; 42(4):265-72. PubMed ID: 16687897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
    Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
    Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resuscitating patients with early severe sepsis: a Canadian multicentre observational study.
    McIntyre LA; Fergusson D; Cook DJ; Nair RC; Bell D; Dhingra V; Hutton B; Magder S; Hébert PC;
    Can J Anaesth; 2007 Oct; 54(10):790-8. PubMed ID: 17934160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial resuscitation guided by the Surviving Sepsis Campaign recommendations and early echocardiographic assessment of hemodynamics in intensive care unit septic patients: a pilot study.
    Bouferrache K; Amiel JB; Chimot L; Caille V; Charron C; Vignon P; Vieillard-Baron A
    Crit Care Med; 2012 Oct; 40(10):2821-7. PubMed ID: 22878678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing mortality in severe sepsis and septic shock.
    Levinson AT; Casserly BP; Levy MM
    Semin Respir Crit Care Med; 2011 Apr; 32(2):195-205. PubMed ID: 21506056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality.
    Nguyen HB; Corbett SW; Steele R; Banta J; Clark RT; Hayes SR; Edwards J; Cho TW; Wittlake WA
    Crit Care Med; 2007 Apr; 35(4):1105-12. PubMed ID: 17334251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.